OIVD Becomes OIR: FDA Diagnostic Office Adds Entire Radiological Health Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency has fully incorporated all of its post-market radiological health regulatory programs into its newly-named Office of In Vitro Diagnostics and Radiological Health.
You may also be interested in...
Regulatory News In Brief
Radiological health post-market offices moving to OIVD. FDA issues global engagement report. More regulatory news.
Radiology Devices Move To OIVD: More Cohesive Dx Reviews Ahead?
FDA hopes that shuttling its Radiological Devices Branch to the Office of In Vitro Diagnostic Device Evaluation and Safety will produce more cohesive policies on diagnostic device review
CDRH Focusing On New PMA Pathway, Clinical Trials Program In 2014/2015 Priorities
CDRH Director Jeffrey Shuren discussed the device center’s two-year strategic priorities with “The Gray Sheet.” The center plans to rebalance pre-market and post-market data collection, when appropriate, and improve the processes for starting up clinical trials in the U.S.